Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol Falls Further Behind Merck In NSCLC By Pulling Early Combo Filing

Executive Summary

Bristol-Myers Squibb's decision not to seek accelerated FDA approval for its Opdivo/Yervoy combo in early lung cancer shocked investors - but analysts still expect a filing to come, albeit later than first thought.


Related Content

Bristol's Opdivo/Yervoy Combo Beats Sutent On Survival In Renal Cancer
Combinations Continue To Drive Immuno-Oncology Deal-Making
Bristol's New CSO Lynch Defends Lung Cancer Plans, Proclaims R&D Priorities
Few Q1 Bright Spots For AstraZeneca Puts Pressure On The Pipeline
IDO Emerges As Clean Combo Partner, Rising Star At AACR
Merck Stretches Lead As EU Approves Keytruda In First-Line NSCLC
AstraZeneca Updates MYSTIC Plan In Bid To Challenge Merck In NSCLC
Bristol Still Rules Immuno-Oncology, But For How Long?
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo
What's Next For Bristol's Opdivo/Yervoy Combination


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts